Previous studies have substantiated that PD‐1/Her2 BsAbs have dual blocking activities of Her2 and PD‐1 through in vivo/in vitro experiments and yield a killing effect on Her2‐positive cancers through antibody‐dependent cytotoxicity.[10] In addition, PD‐1/Her2 bispecific antibodies can crosslink Her2‐positive tumor cells and PD‐1‐positive T cells to immune synapses, thereby directing tumor cell killing without antigen recognition, providing a new approach with potential therapeutic benefits that mAbs cannot provide.[11, 12, 13, 14, 15]. Here, ERBB2 is linked to neoplasm.